New Advances in Dyslipidemia
Dyslipidemia is an important risk factor for atherosclerotic cardiovascular disease (ASCVD). However, despite current traditional therapies (e.g., statins), significant residual risks for the onset of ASCVD remain, warranting the need to better understand newer therapeutic options for diminishing t...
Đã lưu trong:
| Định dạng: | Online |
|---|---|
| Ngôn ngữ: | Tiếng Anh |
| Được phát hành: |
MDPI - Multidisciplinary Digital Publishing Institute
2024
|
| Những chủ đề: | |
| Truy cập trực tuyến: | ONIX_20240514_9783036598710_98 |
| Các nhãn: |
Không có thẻ, Là người đầu tiên thẻ bản ghi này!
|
| _version_ | 1869527516507537408 |
|---|---|
| collection | Directory of Open Access Books |
| description | Dyslipidemia is an important risk factor for atherosclerotic cardiovascular disease (ASCVD). However, despite current traditional therapies (e.g., statins), significant residual risks for the onset of ASCVD remain, warranting the need to better understand newer therapeutic options for diminishing this prospect. This Special Issue will focus on state-of-the-art concepts in the evaluation and management of dyslipidemia, including the rationale for newly set goals in the lipid treatment of this disease given the recent international guidelines, global trends in the epidemiology of dyslipidemia, the latest concepts and therapies in the evaluation and management of familial hypercholesterolemia, novel therapies for lowering LDL-C beyond statin therapy, the status of lipoprotein(a) as a causal risk factor and newer therapeutic approaches to address it, the evaluation and management of dyslipidemia in children, current and emerging therapies for hypertriglyceridemia, and nutraceuticals to treat dyslipidemia in patients with COVID-19. This Special Issue will discuss state-of-the-art clinical trials and other research developments regarding newer and emerging therapies for the management of dyslipidemia to reduce the residual risks of ASCVD. The hope is to provide clinicians with the latest information on the key aspects of the evaluation and treatment of dyslipidemia, including newer non-statin approaches for decreasing the residual risks of ASCVD, such as the settings of elevated LDL-C, lipoprotein(a), and familial hypercholesterolemia. |
| format | Online |
| id | doab-20.500.12854ir-137496 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2024 |
| publishDateRange | 2024 |
| publishDateSort | 2024 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1374962024-05-14T13:18:23Z New Advances in Dyslipidemia Wong, Nathan n/a dyslipidemia cardiovascular disease prevention treatment risk factors atherosclerosis peripheral artery disease intermittent claudication amputation critical limb ischemia lipoprotein statin PCSK9 inhibitors icosapent ethyl inclisiran lipoprotein(a) epidemiology guidelines therapy management pediatric atherosclerotic cardiovascular disease familial hypercholesterolemia cholesterol screening universal screening PCSK9 ANGPTL3 risk management secondary prevention primary prevention ANGPTL3 inhibitors evinacumab LDL cholesterol fibrates lipids lipoproteins niacin omega-3 fatty acids statins triglycerides diabetes mellitus LDL-cholesterol apolipoprotein B cardiometabolic cardiovascular risk reduction complementary medicine integrative medicine lipoprotein (a) low density lipoprotein cholesterol thema EDItEUR::M Medicine and Nursing Dyslipidemia is an important risk factor for atherosclerotic cardiovascular disease (ASCVD). However, despite current traditional therapies (e.g., statins), significant residual risks for the onset of ASCVD remain, warranting the need to better understand newer therapeutic options for diminishing this prospect. This Special Issue will focus on state-of-the-art concepts in the evaluation and management of dyslipidemia, including the rationale for newly set goals in the lipid treatment of this disease given the recent international guidelines, global trends in the epidemiology of dyslipidemia, the latest concepts and therapies in the evaluation and management of familial hypercholesterolemia, novel therapies for lowering LDL-C beyond statin therapy, the status of lipoprotein(a) as a causal risk factor and newer therapeutic approaches to address it, the evaluation and management of dyslipidemia in children, current and emerging therapies for hypertriglyceridemia, and nutraceuticals to treat dyslipidemia in patients with COVID-19. This Special Issue will discuss state-of-the-art clinical trials and other research developments regarding newer and emerging therapies for the management of dyslipidemia to reduce the residual risks of ASCVD. The hope is to provide clinicians with the latest information on the key aspects of the evaluation and treatment of dyslipidemia, including newer non-statin approaches for decreasing the residual risks of ASCVD, such as the settings of elevated LDL-C, lipoprotein(a), and familial hypercholesterolemia. 2024-05-14T13:18:17Z 2024-05-14T13:18:17Z 2024 book ONIX_20240514_9783036598710_98 9783036598710 9783036598727 https://directory.doabooks.org/handle/20.500.12854/137496 eng application/octet-stream Attribution-NonCommercial-NoDerivatives 4.0 International https://mdpi.com/books/pdfview/book/8654 https://mdpi.com/books/pdfview/book/8654 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-9872-7 10.3390/books978-3-0365-9872-7 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036598710 9783036598727 214 open access |
| spellingShingle | n/a dyslipidemia cardiovascular disease prevention treatment risk factors atherosclerosis peripheral artery disease intermittent claudication amputation critical limb ischemia lipoprotein statin PCSK9 inhibitors icosapent ethyl inclisiran lipoprotein(a) epidemiology guidelines therapy management pediatric atherosclerotic cardiovascular disease familial hypercholesterolemia cholesterol screening universal screening PCSK9 ANGPTL3 risk management secondary prevention primary prevention ANGPTL3 inhibitors evinacumab LDL cholesterol fibrates lipids lipoproteins niacin omega-3 fatty acids statins triglycerides diabetes mellitus LDL-cholesterol apolipoprotein B cardiometabolic cardiovascular risk reduction complementary medicine integrative medicine lipoprotein (a) low density lipoprotein cholesterol thema EDItEUR::M Medicine and Nursing New Advances in Dyslipidemia |
| title | New Advances in Dyslipidemia |
| title_full | New Advances in Dyslipidemia |
| title_fullStr | New Advances in Dyslipidemia |
| title_full_unstemmed | New Advances in Dyslipidemia |
| title_short | New Advances in Dyslipidemia |
| title_sort | new advances in dyslipidemia |
| topic | n/a dyslipidemia cardiovascular disease prevention treatment risk factors atherosclerosis peripheral artery disease intermittent claudication amputation critical limb ischemia lipoprotein statin PCSK9 inhibitors icosapent ethyl inclisiran lipoprotein(a) epidemiology guidelines therapy management pediatric atherosclerotic cardiovascular disease familial hypercholesterolemia cholesterol screening universal screening PCSK9 ANGPTL3 risk management secondary prevention primary prevention ANGPTL3 inhibitors evinacumab LDL cholesterol fibrates lipids lipoproteins niacin omega-3 fatty acids statins triglycerides diabetes mellitus LDL-cholesterol apolipoprotein B cardiometabolic cardiovascular risk reduction complementary medicine integrative medicine lipoprotein (a) low density lipoprotein cholesterol thema EDItEUR::M Medicine and Nursing |
| topic_facet | n/a dyslipidemia cardiovascular disease prevention treatment risk factors atherosclerosis peripheral artery disease intermittent claudication amputation critical limb ischemia lipoprotein statin PCSK9 inhibitors icosapent ethyl inclisiran lipoprotein(a) epidemiology guidelines therapy management pediatric atherosclerotic cardiovascular disease familial hypercholesterolemia cholesterol screening universal screening PCSK9 ANGPTL3 risk management secondary prevention primary prevention ANGPTL3 inhibitors evinacumab LDL cholesterol fibrates lipids lipoproteins niacin omega-3 fatty acids statins triglycerides diabetes mellitus LDL-cholesterol apolipoprotein B cardiometabolic cardiovascular risk reduction complementary medicine integrative medicine lipoprotein (a) low density lipoprotein cholesterol thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20240514_9783036598710_98 |